지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 347 - 354 (8page)
이용수
초록· 키워드
오류제보하기
A treat-to-target strategy, in which treatment is continuously adjusted according to the results of scheduled objective monitoring, is optimal for patients with Crohn’s disease (CD) in the era of biologics. The small bowel is a common site of intractable CD, which may result from multiple strictures or expanding lesions. To improve the prognosis of patients with small bowel CD, lesions should be proactively monitored within the subclinical phase. Objective assessment of small bowel lesions is technically difficult, however, due to the relatively poor correlation between endoscopic activity and clinical symptoms or biomarker titers. The presence of proximal small bowel lesions and asymptomatic “Real Silent CD” must be considered. Endoscopy remains the gold standard to assess these lesions. In clinical practice, the advantages and disadvantages of each imaging modality and biomarker must be carefully weighed for appropriate application and reliable monitoring. The prevalence of small bowel lesions depends on the precision of the imaging modality used for detection. Clinical management should be based on the dominant location of the intestinal lesions rather than classical classification. Optimal strategies for detecting and treating small bowel lesions in patients with CD must be developed utilizing reliable, precise, and objective monitoring.
목차
등록된 정보가 없습니다.
참고문헌 (56)
참고문헌 신청
Murakami Y / 2019 / Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014 : an analysis of a nationwide survey / J Gastroenterol 54:1070~1077
Wee Khoon Ng / 2016 / Changing epidemiological trends of inflammatory bowel disease in Asia / Intestinal research 14(2):111~119
Liu JZ / 2015 / Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations / Nat Genet 47:979~986
Watanabe K / 2020 / Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses / J Gastroenterol 55:291~306
Miyazaki T / 2020 / Efficacies and related issues of ustekinumab in Japanese patients with Crohn’s disease : a preliminary study / Digestion 101:53~59
Wee Khoon Ng / 2016 / Changing epidemiological trends of inflammatory bowel disease in Asia / Intestinal research 14(2):111~119
Liu JZ / 2015 / Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations / Nat Genet 47:979~986
Watanabe K / 2020 / Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses / J Gastroenterol 55:291~306
Miyazaki T / 2020 / Efficacies and related issues of ustekinumab in Japanese patients with Crohn’s disease : a preliminary study / Digestion 101:53~59
이 논문의 저자 정보
최근 본 자료
댓글(0)
0